| Autor: |
Sentís A; Epidemiology Department, Epiconcept, Paris, France., Kislaya I; Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisbon, Portugal., Nicolay N; Vaccine preventable diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden., Meijerink H; Norwegian Institute of Public Health (NIPH), Oslo, Norway., Starrfelt J; Norwegian Institute of Public Health (NIPH), Oslo, Norway., Martínez-Baz I; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.; CIBER on Epidemiology and Public Health (CIBERESP), Madrid, Spain., Castilla J; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.; CIBER on Epidemiology and Public Health (CIBERESP), Madrid, Spain., Nielsen KF; Statens Serum Institut (SSI), Copenhagen, Denmark., Hansen CH; Statens Serum Institut (SSI), Copenhagen, Denmark., Emborg HD; Statens Serum Institut (SSI), Copenhagen, Denmark., Nardone A; Epidemiology Department, Epiconcept, Paris, France., Derrough T; Vaccine preventable diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden., Valenciano M; Epidemiology Department, Epiconcept, Paris, France., Nunes B; Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisbon, Portugal., Monge S; Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; CIBER on Infectious Diseases (CIBERINFEC), Madrid, Spain. |
| Abstrakt: |
By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65-79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant. |
